NAD

ChromaDex Reports FDA’s Conclusion that Nicotinamide Mononucleotide (NMN) May Not Be Sold or Marketed as a Dietary Supplement in the United States

Retrieved on: 
Friday, November 11, 2022

NMN cannot cross the cell membrane directly and must first be converted to nicotinamide riboside or NR, making NR a more efficient nicotinamide adenine dinucleotide (NAD+) precursor.

Key Points: 
  • NMN cannot cross the cell membrane directly and must first be converted to nicotinamide riboside or NR, making NR a more efficient nicotinamide adenine dinucleotide (NAD+) precursor.
  • Supplementation with Niagen is backed by over 20 published and peer-reviewed clinical trials, over 200 published scientific studies and over 40 owned and licensed patents.
  • The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age.
  • ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen.

Branded Legacy, Inc. Acquires Total Refinement Solutions, LLC

Retrieved on: 
Wednesday, November 9, 2022

Total Refinement Solutions LLC is a newly formed limited liability company based on years of experience in the cannabis industry, training growers how to compete in the highly demanding industry.

Key Points: 
  • Total Refinement Solutions LLC is a newly formed limited liability company based on years of experience in the cannabis industry, training growers how to compete in the highly demanding industry.
  • Total Refinement Solutions has developed no less than four potential standard operating procedures for extraction, refinement and synthesis of any given target alkaloid.
  • It has secured inputs of raw plant material, crude extracts for refinement and a demand for the output.
  • We are very excited to be moving forward with Total Refinement Solutions and their management team.

Branded Legacy, Inc. Signs Letter Of Intent to Purchase Total Refinement Solutions, LLC

Retrieved on: 
Friday, November 4, 2022

Total Refinement Solutions LLC is a newly formed limited liability company based on years of experience in the cannabis industry, training growers how to compete in the highly demanding industry.

Key Points: 
  • Total Refinement Solutions LLC is a newly formed limited liability company based on years of experience in the cannabis industry, training growers how to compete in the highly demanding industry.
  • Total Refinement Solutions has developed no less than four potential standard operating procedures for extraction, refinement and synthesis of any given target alkaloid.
  • It has secured inputs of raw plant material, crude extracts for refinement and a demand for the output.
  • Brandon Spikes, chairman of Branded Legacy, Inc., stated, This letter of intent puts us one step closer to full vertical integration.

Irwin Naturals Looks to Add to Florida Foothold in Expanding Chain of Healthcare Clinics

Retrieved on: 
Thursday, November 3, 2022

Those clinics will join Irwin Naturals Emergence, a fast-growing national chain offering psychedelic mental healthcare that already includes five clinics in Florida.

Key Points: 
  • Those clinics will join Irwin Naturals Emergence, a fast-growing national chain offering psychedelic mental healthcare that already includes five clinics in Florida.
  • Klee Irwin, CEO of Irwin Naturals said, Were not just acting fast, were acting first with the goal of building the biggest chain of psychedelic mental-healthcare clinics in the country, and Florida is becoming a cornerstone.
  • As of Sept. 6, 2022, Irwin Naturals Emergence had reached agreements with 11 clinics across seven different states, including five clinics in Florida .
  • Klee Irwin, Irwin Naturals CEO, We will be a beacon in this new area of mental healthcare.

LifeVantage Announces Financial Results for the First Quarter of Fiscal 2023

Retrieved on: 
Wednesday, November 2, 2022

SALT LAKE CITY, Nov. 02, 2022 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN) today reported financial results for its first fiscal quarter ended September30, 2022.

Key Points: 
  • SALT LAKE CITY, Nov. 02, 2022 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN) today reported financial results for its first fiscal quarter ended September30, 2022.
  • * All comparisons are on a year over year basis and compare the first quarter of fiscal 2023 to the first quarter of fiscal 2022, unless otherwise noted.
  • For the first fiscal quarter ended September30, 2022, the Company reported revenue of $51.8 million, a 2.7% decrease over the first quarter of fiscal 2022.
  • Operating income for the first quarter of fiscal 2023 was $1.3 million compared to $4.6 million for the first quarter of fiscal 2022.

ChromaDex Corporation Reports Third Quarter 2022 Financial Results

Retrieved on: 
Wednesday, November 2, 2022

ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the third quarter of 2022.

Key Points: 
  • ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the third quarter of 2022.
  • Total net sales were $17.1 million, with $14.6 million from Tru Niagen, down (1)% each from the prior year quarter.
  • Net loss was $1.0 million or $(0.01) per share, an improvement of $0.12 per share from the prior year quarter.
  • We approached cash flow break even in the third quarter and remain on track to achieve this important objective next quarter, said ChromaDex CEO, Rob Fried.

OrsoBio Acquires ACMSD Inhibitor Program to Address Mitochondrial Dysfunction from Mitobridge, an Astellas Company

Retrieved on: 
Wednesday, November 2, 2022

OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced its acquisition of an ACMSD inhibitor program from Mitobridge, an Astellas Company.

Key Points: 
  • OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced its acquisition of an ACMSD inhibitor program from Mitobridge, an Astellas Company.
  • The program includes a range of proprietary compounds being evaluated for their potential to address mitochondrial dysfunction in metabolic and inflammatory liver and kidney disorders.
  • ACMSD is highly expressed in the liver and kidneys and NAD+ is reduced in patients with advanced hepatic and renal disease.
  • TLC-065 and other compounds within the ACMSD inhibitor portfolio are being studied for their potential to replenish NAD+ and improve mitochondrial function.

Practice Interactive Bolsters Healthcare Innovation Across Tech, Wellness, Supplements

Retrieved on: 
Tuesday, November 1, 2022

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221101006030/en/
    The Practice Interactive Group of companies work together and independently to improve the health of healthcare.
  • Practice Interactive is headquartered in Austin, Texasa hotbed for industry trailblazerswith three core entities: Intiva Health, Nova Vita Wellness Centers, and Gummi World.
  • The group of companies creates visionary solutions in software, clinical practice, and nutraceutical manufacturing which offer minimal-risk growth strategies under the umbrella of healthcare.
  • At Practice Interactive, we believe that the healthcare industry is in need of a transformation.

OrsoBio Launches to Develop Novel Therapies for Patients with Severe Metabolic Disorders

Retrieved on: 
Tuesday, November 1, 2022

OrsoBio has initiated preclinical and clinical activities to support advancement of these compounds for the treatment of patients with severe metabolic disorders, including diabetes, severe dyslipidemias, lipodystrophies, and nonalcoholic steatohepatitis (NASH).

Key Points: 
  • OrsoBio has initiated preclinical and clinical activities to support advancement of these compounds for the treatment of patients with severe metabolic disorders, including diabetes, severe dyslipidemias, lipodystrophies, and nonalcoholic steatohepatitis (NASH).
  • Our programs address the root causes of metabolic dysregulation in patients with severe metabolic disorders, said Mani Subramanian, MD, PhD, Founder and CEO of OrsoBio.
  • The OrsoBio approach of targeting multiple fundamental aspects of cellular energetics addresses large unmet patient need in severe metabolic diseases.
  • OrsoBio, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to developing therapies to treat severe metabolic disorders, including type 2 diabetes, severe dyslipidemias, lipodystrophies, and nonalcoholic steatohepatitis.

ChromaDex to Report Third Quarter Financial Results on Wednesday, November 2, 2022

Retrieved on: 
Wednesday, October 26, 2022

ET to discuss its financial results for the third quarter, which ended September 30, 2022.

Key Points: 
  • ET to discuss its financial results for the third quarter, which ended September 30, 2022.
  • The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call.
  • ChromaDex management will host an investor conference call to discuss the third quarter results and provide a general business update on Wednesday, November 2, 2022 at 4:30 p.m.
  • ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.